home > news > detailed info

TrialScope Taps Industry Veteran as CTO


TrialScope Taps Industry Veteran as CTO, Expanding Its Management Team

JERSEY CITY, NJ, July 29, 2019 – TrialScope, the global leader in clinical trial transparency and compliance solutions, announces the appointment of Ruben Echandy as Chief Technology Officer.

TrialScope CEO Ruben Echandy“In the clinical and health market, there’s informational chaos. There’s an opportunity for TrialScope to bring visibility, trust and distill further intelligence from that data,” said Echandy. “I also believe a patient deserves a higher level of hyper-personalization from life science technologies, more control over his/her pathology. TrialScope has a strong opportunity to champion this.”

“Life science technology is fast paced and constantly evolving,” said TrialScope CEO Jeff Kozloff. “Ruben’s technical leadership, coupled with his business acumen, make him the ideal fit for TrialScope and our technology team.” Kozloff added that Echandy has a proven track record of attracting and inspiring top talent in all aspects of software delivery life cycles.

In his role as CTO at TrialScope, Echandy sees himself as an evangelist for vision and innovation, using strategic thinking to anticipate emerging market trends. As with any TrialScope undertaking, the desired end result is improved overall customer satisfaction and utility of its products. To that end, Echandy said his goal is to promote a close proximity between customers and engineering, propelling business forward, accelerating TrialScope’s market footprint and adoption of innovation. The key to fostering long-lasting relationships with clients, he said, is “to carefully listen to our customers, and to always be truthful.”

Echandy says he is looking forward to working on new technologies and working with his IT team. “The level of professionalism and utmost dedication to advance the company’s mission was palpable in every conversation I’ve had with Jeff Kozloff and with every member of his executive team."

Kozloff echoes staffers’ excitement at this new addition to the TrialScope team. “At TrialScope, we continuously reinvest in our software platform,” said Kozloff. “To do so effectively, we must also invest in the expertise behind these market-leading compliance and patient engagement solutions. This is why I am extremely pleased to have Ruben lead our tech group. I am confident that, in his hands, we will make even greater strides with our technology, enabling our clients to expand upon their commitments to clinical trial disclosure, data sharing and transparency.”

Over the last 14 years, Echandy has managed both small and large teams at well-respected engineering organizations. Having led global teams through a variety of challenges, Echandy said he is ready to accelerate on every sharp corner that comes his way. Prior to joining TrialScope, Echandy served as Senior Director of Engineering at Medidata Solutions, a software company also catering to the pharmaceutical industry. His previous positions include serving as Senior Consultant for several IT firms and as Vice President of Engineering at Digital Guardian.

“I enjoy accelerating growth companies,” said Echandy, “and am fearless in charging forward.”

For more information on TrialScope, visit

About TrialScope
TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions that optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit
phone 1-877-658-8310
web www.
email 185 Hudson Street, Suite 2900
Print this page
Send to a friend
News and Press Releases

Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules

European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement